Blocking the activation of AKT by MK2206, a phase II inhibitor of AKT for breast cancer patients, rescued E-cadherin expression (Fig. 4D) and suppressed CCT8-induced cell-scattered growth (Fig. 4E), cell migration (Fig. 4F), cell mobility (Fig. 4G) and tumor metastasis (Fig. 4H-4I). Here, CDH1 is linked to breast carcinoma.